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A B S T R A C T
Question:What are typical values of physical function for women diagnosedwith breast cancer and how
do these compare to normative data? Design: Systematic review with meta-analysis. Participants:
Women diagnosed with breast cancer who were before, during or after treatment. Outcome measures:
Physical function was divided into three categories: aerobic capacity, upper and lower extremity
muscular ﬁtness, andmobility. Measures of aerobic capacity included ﬁeld tests (6-minutewalk test, 12-
minute walk tests, Rockport 1-mile test, and 2-km walk time) and submaximal/maximal exercise tests
on a treadmill or cycle ergometer. Measures of upper and lower extremitymuscular ﬁtness included grip
strength, one repetition maximum (bench, chest or leg press), muscle endurance tests, and chair stands.
The only measure of mobility was the Timed Up and Go test. Results: Of the 1978 studies identiﬁed,
85 were eligible for inclusion. Wide ranges of values were reported, reﬂecting the range of ages, disease
severity, treatment type and time since treatment of participants. Aerobic ﬁtness values were generally
below average, although 6-minute walk time was closer to population norms. Upper and lower
extremity strength was lower than population norms for women who were currently receiving cancer
treatment. Lower extremity strength was above population norms for women who had completed
treatment. Conclusion: Aerobic capacity and upper extremity strength in women diagnosedwith breast
cancer are generally lower than population norms. Assessment of values for lower extremity strength is
less conclusive. Asmore research is published, expected values for sub-groups by age, treatment, and co-
morbidities should be developed. [Neil-Sztramko SE, Kirkham AA, Hung SH, Niksirat N, Nishikawa K
Campbell KL (2014) Aerobic capacity and upper limb strength are reduced in women diagnosed
with breast cancer: a systematic review. Journal of Physiotherapy 60: 189–200]
 2014 Australian Physiotherapy Association. Published by Elsevier B.V. This is an open access article
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).Introduction
Worldwide, breast cancer remains the most commonly
diagnosed cancer in women.1 Due to advancements in treatment
approaches for breast cancer, the 5-year survival rate has
improved dramatically, and in Canada is approximately 88%.2
Despite the efﬁcacy of treatment in improving survival, women
who have undergone treatment for breast cancer face both acute
and chronic impairments in various aspects of physical function
as a result of their treatment, which may involve a combination
of surgery, chemotherapy, radiation therapy, hormonal therapy
or other targeted biological therapies.3 Physiotherapists have
the potential to play an important role in cancer care by
identifying and monitoring changes in physical function during
and following breast cancer treatment, and by prescribing
interventions to address deﬁcits in physical function. For the
purposes of the present review, three main aspects of physical
function have been selected: aerobic capacity, muscular ﬁtness
of the upper and lower extremities, and mobility. These aspects
of physical function were selected because they represent
clinically relevant areas of focus for physical therapists, theyhttp://dx.doi.org/10.1016/j.jphys.2014.09.005
1836-9553/ 2014 Australian Physiotherapy Association. Published by Elsevier B
creativecommons.org/licenses/by-nc-nd/3.0/).are commonly assessed in exercise oncology literature, and each
has established objective outcome measures available for
comparison.
Aerobic capacity
Declines in aerobic capacity have been observed during breast
cancer treatment, which is likely a combination of the direct and
indirect effects of the treatment itself, and associated reduction in
physical activity leading to deconditioning.4 Maximal oxygen
consumption (VO2max) – the upper limit to the rate of oxygen
utilisation, asmeasured by a cardiopulmonary exercise test – is the
gold standard measurement of cardiorespiratory ﬁtness and the
capacity for physical work.5 In clinical populations, VO2max may
not be achieved during a cardiopulmonary exercise test, so the
peak oxygen consumption (VO2peak) is used instead. VO2peak is
associated with all-cause,6 cardiovascular disease-speciﬁc7,8 and
breast cancer-speciﬁc9 mortality. A recent cross-sectional study
reported that women diagnosed with breast cancer have a
VO2peak on average 27% lower than that expected for healthy
sedentary women.10.V. This is an open access article under the CC BY-NC-ND license (http://
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outcomes, cardiopulmonary exercise testing requires expensive,
specialised equipment and medical supervision for high-risk
individuals, thereby limiting its feasibility. A submaximal exercise
test, such as a progressive exercise test that is terminated at 85% of
age-predicted maximal heart rate or 70% of heart rate reserve, is
often a more feasible alternative in clinical practice because it poses
less risk and can be done without collection of expired metabolic
gases. VO2max can be estimated with a submaximal exercise test.
11
The 6-minute walk test (6MWT) is a widely used ﬁeld test that
offers a more practical approach to quantifying physical capacity
than maximal or submaximal cardiopulmonary exercise tests. The
6MWT measures the distance walked over a ﬂat, hard surface
in 6 minutes.12 The 6MWT distance correlates with VO2peak
(r = 0.59 to 0.73)12,13 and is more a measure of an individual’s
ability to perform daily activities than a surrogate measure of
aerobic capacity.12 Although there is concern regarding the need
for a familiarisation trial to account for a potential learning effect,
the test-retest reliability of the 6MWT was recently reported for a
cancer population (ICC = 0.93, 95% CI 0.86 to 0.97), and the 6MWT
was signiﬁcantly correlated with VO2peak (r = 0.67).
14 Other ﬁeld
tests assessing aerobic capacity without the need for expensive
equipment include the Cooper 12-minute walk test (12MWT),12
Rockport 1-mile test15 and 2-km walk time.16
Upper and lower extremity muscular ﬁtness
Muscularﬁtness isa componentofphysical function thatconsists
ofmuscular strength, endurance and power.11 Following surgery for
breast cancer, women may experience substantial impairment in
upper extremity function. Functional limitations, including decline
in strength and range of motion, may continue after acute recovery
from surgery is complete.17 Deconditioning during active cancer
treatment (ie, chemotherapy and radiation) may also contribute to
declines in upper and lower extremity strength and endurance.
Aromatase inhibitors, commonly prescribed following the comple-
tionof chemotherapyand radiation therapy, are alsoassociatedwith
musculoskeletal symptoms such as pain, which may also reduce
participation in physical activity, further contribute to decondition-
ing and, in turn, impact muscular ﬁtness.18
Muscular strength refers to the ability to exert force. The gold
standard for assessment ofmuscle strength is the force exerted in a
maximum voluntary contraction with force output measured by a
computerised dynamometer.19 This type of equipment is very
expensive and, thus, not commonly used outside of a research
setting. In the ﬁeld, strength is traditionally evaluated with a one
repetition maximum (1RM) or maximum voluntary contraction,
but four to 15 repetition tests to estimate 1RM have also been used
to assess strength.11 General upper extremity strength is typically
assessed using a chest or bench press, while lower extremity
strength is commonly assessed using leg press or leg extension.11
Alternatively, muscle strength can be measured objectively in a
clinical setting using a portable, tester-reliant tool called a hand-
held dynamometer. Inter-tester reliability coefﬁcients for this tool
range from –0.19 to 0.99, depending on the study, and appears to
be more reliable for upper than lower body strength measure-
ments.20 Muscular endurance refers to the ability to successively
perform exertions of force and is evaluated via the maximum
number of repetitions at a percentage of the 1RM or body weight,
oftenwith the repetitions performed at a standard rate.11 The chair
stand test is another commonly used ﬁeld test of lower body
strength and involves either the number of chair stands performed
in 30 seconds or the amount of time required to perform a
predetermined number of chair stands. The 30-second chair stand
has moderately high test-retest reliability (ICC = 0.89) and
moderate construct validity as demonstrated by a correlation
with the leg press (r = 0.77).21
Finally, a commonly reported measure of global muscular
strength is grip strength. Due to the internal consistency of strength
measurements, grip strength may be used to characterise overallstrength and has been shown to be a predictor of postoperative
complications, functional limitations, disability and mortality.22
Mobility
Mobility assessment is intended to be a functional measure that
is inﬂuenced by bothmuscular strength and agility. A common ﬁeld
test, the Timed Up and Go (TUG) test, requires a participant to
perform a sequence of tasks that are all critical for independent
mobility: rise from a chair, walk 3metres, turn around, walk back to
the chair, and sit down.23 The test outcome is the total time required
to complete the sequence. As such, the TUG test provides an overall
assessment of mobility and does not identify problems with
particular tasks.23 This test is reliable and valid for quantifying
functional mobility and for assessing clinical change over time.24
Although intra-rater and inter-rater reliability of the test are high
(ICC = 0.92 to 0.96), test-retest reliability is moderate (ICC = 0.56),25
which ispotentially due toa learningeffect. Construct validityof this
functional test has been supported by correlationswith a number of
functional measurements including: gait speed (r = 0.75), postural
sway (r = 0.48), step length (r = 0.74), stair test (r = 0.59) and step
frequency (r = 0.59).25 Other assessments of mobility include
measuring gait speed, time to ascend or descend a certain number
of stairs, and the time it takes to get down and up from the ﬂoor.
In healthy populations, normative values of a variety of the tests
described above have been published. These values help phy-
siotherapists and other health professionals interpret a patient’s
result on a speciﬁc test relative to others of similar age and gender
and may provide a goal for individuals and clinicians to attain.
Research to date has documented the decline in various aspects of
physical function during and following breast cancer treatment. In
order to publish average values for this clinical population, a large
sample of participants is required. The aim of this review was to
summarise the available data that have been published in studies
that measured physical function in women who have been
diagnosed with breast cancer, to generate a resource for
physiotherapists using the tests that are most commonly used
in this ﬁeld of research. The second aim is to compare reported
values to published normative data, where available.
Methods
Identiﬁcation and selection of studies
Due to the wide range of assessment tools available, the review
was limited to the most commonly used, objective and validated
tests reported in the exercise oncology literature that would also
be relevant to physiotherapists, as identiﬁed in a previous
literature review.26 A list of MeSH terms and key words related
to breast cancer, physical function, and the speciﬁc outcomes of
interest were developed (see Appendix 1 in the eAddenda).
MEDLINE, Embase and CINAHLwere searched using these terms up
to and including 27 December, 2012. Included studies were
required to meet all inclusion criteria (Box 1). Case studies were
excluded, as were studies including participants with other types
of cancer, unless values were reported separately by cancer type.
Studies that were limited to women with metastatic breast cancer
were also excluded; however, we did not otherwise exclude
studies on the basis of individual study eligibility criteria. Lack of
consensus about eligibility was resolved through discussion.
Data extraction and synthesis
Relevant data were extracted from each identiﬁed paper,
including demographic characteristics of the study participants,
details of the study design, name of the test used, speciﬁcs of the
test protocol, and reported values of the selected physical function
tests. Data were extracted for the full study sample where
available, and separate group data were pooled for simplicity.27
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Figure 1. Flow of studies through the review.
Box 1. Inclusion criteria.
Design
 Randomised trials
 Non-randomised intervention studies
 Observational studies
Participants
 Women diagnosed with breast cancer
 Before, during or after treatment
Intervention
 Any intervention or no intervention
Outcome measures
 Aerobic capacity (maximal or submaximal exercise test,
six or twelve minute walk test, Rockport 1-mile test, 2-km
walk time)
 Upper extremity strength and endurance (grip strength,
bench/chest press)
 Lower extremity strength and endurance (leg press, knee
flexion/extension, chair stands)
 Mobility (Timed Up and Go)
Research 191A second author checked the data extraction. Where baseline
values of outcomes of interest were not reported, authors were
contacted for missing data. Of 13 authors contacted, data were
received from three. Where necessary, data were converted to
metric units. The selection of the age range for normative values
reported was based on the average age and mean body weight of
participants in the included studies.
Data analysis
For outcomes in which at least three different studies used a
comparable protocol, a meta-analysis was conducted. Using
methods described by Neyeloff et al27 for descriptive data analysis,
the pooled mean for each outcome was calculated using a random-
effects model. Studies for which the mean and standard deviation
were not reported in the paper (eg, median and/or range were
reported instead)werenot included in themeta-analysis. All studies
reporting the speciﬁc outcome of interest were plotted on the same
forest plot, however pooled means were calculated separately for
studies involving participants who were ‘on treatment’ and ‘off
treatment’. ‘On treatment’ was deﬁned as measures taken prior to
the completion of surgery, chemotherapy or radiation therapy. ‘Off
treatment’ was deﬁned as studies in which authors report that
participantshadcompleted surgery, chemotherapy and/or radiation
therapy, but may have still been taking hormonal therapies.
Heterogeneity was assessed using I2 under the random-effects
model using the methods described by Neyeloff et al.27
Results
The search identiﬁed 1978 papers, of which 361 were retrieved
and screened for eligibility and 85 met our inclusion criteria
(Figure 1). A full list of included studies can be found in Appendix 2
(in the eAddenda). The most common reasons for exclusion were
that the outcomes assessed did not meet the inclusion criteria, or
the studies did not examine women diagnosed with breast cancer.
Study designs and relevant participant characteristics are listed in
Table 1. Of the studies included, 42 were randomised trials,
19 were non-randomised intervention studies, and 24 were
observational studies with no intervention. Themajority of studies
(n = 61) included women who were off treatment, while others
included women following surgery but before chemotherapy/
radiation therapy (n = 20) and/or during chemotherapy/radiation
therapy (n = 9), and for the purposes of the present review were
classiﬁed as on treatment (n = 28). Some observational studies
included assessments at multiple time points andwere included in
both groups. Normative values for comparison are presented in
Table 2.Aerobic capacity
The most common test used to assess aerobic capacity was a
maximal cardiopulmonary exercise test (n = 16) using either a
cycle ergometer (n = 9) or treadmill (n = 8) protocol (see Table 3 in
the eAddenda). Pooled relative VO2peakwas amean of 23.7 mL/kg/
min (95% CI 20.4 to 27.0) for women on treatment and 22.8 mL/kg/
min (95% CI 20.7 to 24.9) for women off treatment (Figure 2). The
pooled absolute VO2peakwas amean of 1.65 L/min (95% CI: 1.59 to
1.72) from study groups on treatment and 1.60 L/min (95% CI
1.48 to 1.72) from study groups off treatment (Figure 3). Compared
to published normative data, pooledmeans of VO2peak fell into the
‘very poor’ category for women age 50 to 59 (Table 2).11 No
heterogeneity was identiﬁed (all I2 values < 30%).
Submaximal exercise tests were used to predict VO2max in
15 studies, more commonly using a treadmill (n = 12) than a cycle
ergometer (n = 3) protocol. Predicted VO2max values tended to be
higher than measured VO2peak. The pooled mean for predicted
VO2max forwomen on and off treatmentwas 25.2 mL/kg/min (95%
CI 19.1 to 31.3) and 23.9 mL/kg/min (95% CI 22.5 to 25.4),
respectively (Figure 4). These mean values fall into the ‘very poor’
category for women age 50 to 59 (Table 2).11 No heterogeneity was
identiﬁed (all I2 values < 30%).
The 6MWT was used as a measure of aerobic capacity in nine
studies. The pooled mean value for distance walked was 523 m
(95% CI 499 to 548) for women on treatment, and 500 m (95% CI
476 to 524) inwomen off treatment (Figure 5). These pooledmeans
fall between the 25th and 50th percentiles of community-dwelling
adults aged 60 to 64 (Table 2).28 The 12MWT was used in
11 studies. The pooledmean value for distancewalkedwas 1020 m
(95% CI 982 to 1058) in women on treatment and 904 m (95% CI
831 to 976) in women off treatment (Figure 6). All I2 values
were < 30% except for the 6MWT in the off-treatment groups only,
which had moderate heterogeneity. Other less commonly used
tests include the 2-km walk time with values ranging from 16.9 to
18.9 minutes, and Rockport 1-mile test (reported values of
17.45 and 17.65 minutes). There were no published norms
identiﬁed for the 12MWT, 2-km walk test or Rockport 1-mile test.
Table 1
Included studies, study design and patient characteristics. References to included studies are available in Appendix 2 in the eAddenda.
Reference Study
design
Patient characteristics
n Age (yr) BMI (kg/m2) Stage (%) Time since treatment Treatment type (%) Eligibility
criteria
mean
(SD/range)
mean (SD) mean (SD)
On treatment
Anderson 2012 RCT 104 54 (32 to 82) NR I: 49; II: 38; III: 12 0 to 2wk Mast: 50; Lump: 46 No LD
Beurskens 2007 RCT 30 55 (11) NR NR 2wk Mast: 77; Lump: 23; ALND: 100 Shoulder pain >1
Campbell 2005 RCT 22 47 (5) NR I-III NA CT: 27; RT: 27; CT+RT: 45 Inactive
Courneya 2007 RCT 242 49 (25 to 78) 27 (6) I: 25; IIA: 41; IIB: 20;
IIIA: 15
NA Lump: 59; Mast: 41; CT: 100 –
Drouin 2005 RCT 21 50 (8) NR DCIS: 24; I: 14; II: 24;
III: 38
NA Sx: 24; Sx+CT: 76; RT: 100 Inactive
Haines 2010 RCT 89 55 (9) NR NR NA Sx: 100; CT: 36; RT: 92; HT: 39 –
Haykowsky 2009 Pre-post 17 53 (7) BW (kg) 78 (21) I: 29; IIA: 35; IIB: 24;
III: 12
Immediately before
Trastuzumab
Mast: 53; Lump: 47; CT: 100 HER1; 50% ejection
fraction
Johansson 2001 Obs 61 56 (10) NR NR Pre-op, 6mo, 1 yr, 2yr Mast: 100; CT: 25; RT: 57; HT: 25 All ALND + Mast
Kaya 2010 Obs 67 54 (12) NR NR 9mo (2 to 67) Mast: 87; Lump: 13; CT: 90; RT: 44 LD node removal
Kilgour 2008 RCT 27 50 (5) BW(kg) 75 (16) NR 3 d post Sx Mast: 100 Mast +ALND Sx
Kim 2006 RCT 41 50 (6) 29 (6) 0: 5; I: 41; II: 37; III: 17 ‘‘Shortly after diagnosis’’ CT: 49; RT: 34; CT+RT: 17 Inactive
Kolden 2002 Pre-post 40 55 (8) BW (lb) 155 (25) I: 32; II: 55; III: 13 83% 12mo post diagnosis Mast: 45; Lump: 60; CT: 65;
RT: 60; HT: 50
–
Ligibel 2010 Pre-post 41 47 (7) NR I: 27; II: 37; III: 34 NA Lump: 34; Mast: 56; CT: 98; RT: 54 Inactive
Mock 1994 RCT 14 44 NR I: 14; II: 86 NA CT: 100; Sx+RT: 79; Mast: 21 –
Mock 2001 Pre-post 50 48 (11) 26 (5) I: 54; II: 40; III: 6 NA Lump: 62; Mast: 38; RT: 64; CT: 36 –
Mock 2005 RCT 119 52 (9) 26 (5) 0: 24; I: 43; II: 30; III: 3 NA CT: 42; RT: 58 Inactive
Morimoto 2003 Pre-post 72 50 (10) NR I/II NA Mast: 54; Lump: 46 –
Nikander 2007 RCT 28 52 (5) 28 (5) NR NA CT: 25; HT: 21; CT+HT: 54 –
Postma 1995 Obs 7 56 a (43 to 71) NR NR NA CT: 100 Anthracycline-
resistant; Paclitaxel
Reitman 2003 Obs 204 56 (12) NR I: 42; IIa: 41; IIb: 17 6wk post Sx Mast: 42; Lump: 58 ALND
Rietman 2004 189 I: 42; IIA: 42; IIB: 16 1yr post Sx RT: 67; CT: 34; HT: 38
Reitman 2006 181 2yr post Sx
Schneider 2007 Pre-post 17 56 (10) BW (kg) 68 (12) NR NR Sx: 99; CT: 50; RT: 43 –
Schwartz 2000a Pre-post 27 47 (35 to 57) NR II/III: 70 >21d post Sx Sx: 100 –
Schwartz 2000b Pre-post 71 47 (27 to 71) 23 (0) II: 8; III: 73; IV: 18 >21d post Sx Sx: 100 –
Schwartz 2001 Pre-post 61 47 (8) NR II: 54 >21d post Sx Mast: 74 –
Schwartz 2007 RCT 66 48 (8) BW (kg) 69 (2) I: 23; II: 58; III: 20 NA NR Inactive
Wang 2011 RCT 72 50 (10) BW (kg) 55 (7) I: 22; II: 78 NA NA Chinese; BMI 30
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Table 1 (Continued )
Reference Study
design
Patient characteristics
n Age (yr) BMI (kg/m2) Stage (%) Time since treatment Treatment type (%) Eligibility
criteria
mean
(SD/range)
mean (SD) mean (SD)
Off treatment
Ahmed Omar 2011 RCT 50 54 (3) 27 (5) II/III 40 (9) mo Mast: 82; Lump: 18; RT+CT: 38;
RT+HT: 14; CT+RT+HT: 48
LD
Ahmed 2006 RCT 46 52 (1) 27 (7) DCIS: 4; I: 28; II: 57;
III: 11
IG: 13 (5 to 32); CG:
13 (4 to 37) mo
RT: 74; CT: 87; Sx: 100; HT: 87 Inactive, stable BW
Basen-Engquist 2006 RCT 60 55 (8) 29 (8) DCIS: 22; I: 28; II: 25; III:
18; IV: 3; unknown: 3
IG: 39.2 (16.7); CG:
37.1 (14.1) mo post diagnosis
Lump: 40; Mast 60; None: 12; RT:
22; CT: 22; RT+CT: 45
Inactive
Brdareski 2012 RCT 18 52 (8) 27 (4) I-IIIA IG1: 5 (4); IG2: 3 (3) yr Sx: 100; CT: 72; RT: 72; HT: 50 < 65yr old
Campbell 2012 Pre-post 14 55 (8) 30 (4) I: 7; II: 64; III: 14 24 (22) mo Sx: 7; Sx+RT: 14; Sx+CT: 7;
Sx+RT+CT: 71
BMI 25 to 35; Inactive
Cantarero-
Villanueva 2012a
RCT 67 49 (8) NR I: 24; II: 58; IIIA: 18 <12mo: 76%; >12mo: 24% Lump: 63; Mast: 37; RT: 3; CT:
9; RT+CT: 88
Functional problems
Cantarero-
Villanueva 2012b
Obs 95 NR NR I: 30; II: 53; IIIA: 17 6mo Lump: 68; Mast: 32; HT: 78;
Trastuzumab: 12
Functional problems
Cheema 2006 Pre-post 27 58 (7) BW (kg) 71 (12) DCIS: 7; I: 22; II: 22;
III: 33
5 (5) yr Lump: 59; Mast: 48; RT: 67; CT:
52; HT: 22
Dragon boat team
post season
Courneya 2003 RCT 52 59 (6) 29 (7) I: 40; IIA: 33; IIB: 21;
IIIA: 6
14 (6) mo Mast: 54; Lump: 46; RT: 71; CT:
40; HT: 46
Age 50 to 69yr, PostM
Daley 2007 RCT 108 51 (10) 28 (0) NR IG: 18 (7); ExCG: 18 (7);
CG: 17 (6) mo
Mast: 53; Lump: 47; CT: 74; RT:
79; HT: 73
Inactive
Damush 2006 Pre-post 29 60 (7) NR I: 45; II: 55 3yr post diagnosis Mast: 59; CT: 62  50yr
Dawes, 2008 Obs 50 59 (10) 27 (5) I/II NR Sx: 100% LD symptom
Dolan 2012 Obs 12 55 (6) 26 (6) I: 42; IIA: 50; IIIA: 8 <5yr: 50%; 5 to 10yr:
33%; >10yr: 17% post
diagnosis
Mast: 83; Lump: 17; CT: 83; RT:
75; HT: 58
–
Evans 2009 Obs 7 54 (7) 26 (4) II: 43; III: 57 6mo NR Inactive
Eyigor 2010 RCT 42 49 (6) NR NR IG: 39 (40); CG: 38 (52)
mo post diagnosis
Mast: 100 Inactive
Fillion 2008 RCT 87 52 (10) NR 0: 7; I: 44; II: 35; III: 15 257 (107) d post diagnosis Mast: 14; Lump: 86; CT: 56; RT:
100; HT: 74
–
Garner 2008 Pre-post 11 51 (6) 26 (6) I/II 4 (3) yr post diagnosis NR Inactive, PostM
Hayes 2005 Obs 214 53 (10) NR I: 27; II: 31; III: 32 6mo post diagnosis Mast: 28; Lump: 72; RT: 71;
CT: 41; HT: 42
–
Herrero 2006 RCT 16 50 (8) 25 (4) I: 44; II: 56 36mo Lump: 56; Mast: 44; CT: 100 Inactive, ALND, PostM
Hokken 2009 Pre-post 75 49 (9) 26 (9) NR AC: 23 (13); FEC: 17 (9) wk CT: 100; RT: 73 –
Hsieh 2008 Pre-post 96 58 (10) BW(lb) 168 (39) NR Immediately Mast: 69; Lump: 28, CT: 57; RT: 44 –
Hughes 2008 Obs 25 50 (8) NR I/II: 60; III: 4; IV: 4 61 (35) mo post diagnosis NR Hispanic only
Hutnick 2005 RCT 49 50 (7) 27 (7) I/II: 90 2wk to 2mo Lump: 53; Mast: 45; RT+CT: 71 –
Johansson 2001 Obs 61 56 (10) NR NR Pre-op, 6mo, 1 yr, 2yr CT: 25; RT: 57; HT: 25 All ALND + Mast
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Table 1 (Continued )
Reference Study
design
Patient characteristics
n Age (yr) BMI (kg/m2) Stage (%) Time since treatment Treatment type (%) Eligibility
criteria
mean
(SD/range)
mean (SD) mean (SD)
Jones 2007b Obs 47 57 (7) 28 (5) NR 3yr Lump: 28; Mast: 72; RT: 98; CT: 100 PostM
Jones 2007a Obs 26 48 (9) 29 (6) I/II: 65 20 (10) mo Mast: 52; CT: 100; RT: 65;
HT: 62
Node positive or
high-risk node negative;
operable HER2/neu
Kaltsatou 2011 RCT 27 57 (5) NR NR 2.2 yr NR –
Lane 2005 Pre-post 16 52 (7) 24 (3) I: 44; II: 38; III: 19 >6mo Lump: 75; Mast: 25; Lump+Mast:
25; RT: 94
–
Linterman 2011 Obs 33 AI: 64a (51 to 74);
Tam: 61a (54 to 68)
AI: 24a (18 to 45);
Tam: 23a (21 to 26)
NR NR CT: 12 PostM
Merchant 2008 Obs 40 57 (12) NR NR 29 (21) mo Mast: 40; Lump: 60; CT: 10; RT:
43; CT+RT: 30; HT: 53
Unilateral Sx > 6mo prior
Mulero Portela 2008 RCT 34 51 (6) 30 (6) I: 15; II: 29; III: 26; IV: 3 >2mo Lump: 53; Mast: 47 –
Musanti 2012 RCT 55 51 (8) BW (lb) 169 (36) I: 45; II: 44; III: 11 6wk to 2yr CT: 87; RT: 73; HT: 56 Inactive
Mustian 2006 RCT 21 52 (9) 26 (5) 0/IIIb 1wk to 30mo Lump: 61; Mast: 39; CT: 84;
RT: 61; HT: 56
Inactive
Mutrie 2007 RCT 201 52 (10) 27 (6) 0/III 162 (74) d CT: 8; RT: 28; CT+RT: 64; Mast:
40; Lump: 60
Inactive
Neil 2012 Obs 27 53 (10) 25 (5) I/IIIa F: 21 (18); CG: 23 (19) mo CT+RT: 78; RT: 22; HT: 52 RT
Nikander 2012 RCT 67 53 (8) BW(kg) 72 (16) I: 15; II: 60; III: 25 < 4mo CT: 90; RT: 78; HT: 88 –
Nuri 2012 RCT 29 58 (6) 28 (5) I/IIIb NR NR Inactive, Stable BW, PostM
O&Neill 2006 Pre-post 17 64 (45 to 76) NR NR 3 to 28yr Mast: 100; RT: 29; CT: 12;
RT+CT: 47
LD
Pinto 2005 RCT 86 53 (9) 28 (9) 0: 16; I: 37; II: 47 IG: 2 (1); CG: 2 (1) yr Lump: 72; Mast: 28; RT: 69; CT:
56; HT: 62
Inactive; Diagnosis <5yr
Rietman 2004b Obs 189 56 (12) NR I: 42; IIA: 42; IIB: 16 1yr post Sx RT: 67; CT: 34; HT: 38 ALND
Reitman 2006 181 2yr post Sx
Rietman 2004a Obs 55 57 (13) BW (kg) 74 (17) 0: 4; I: 47; IIa: 35; IIb: 15 3 (1) yr RT: 43; CT: 20 Mast +ALND
Rogers 2009 RCT 41 53 (9) 31 (6) I: 29; II: 51; III: 20 33 (36) mo Sx: 100; CT: 83; RT: 17; HT: 100 Current HT; Inactive
Rogers 2013 RCT 28 56 (11) 32 (5) I: 54; II: 32; III: 14 74 (71) mo post diagnosis Sx: 100; CT: 75; RT: 79; HT: 50 Inactive
Saarto 2012 RCT 498 IG, PreM:
46 (36 to 54); PostM:
58 (48 to 68); CG, PreM:
46 (35 to 57); PostM:
58 (46 to 68)
26 (0) NR IG, PreM: 33.5 (8.2); PostM:
33.9 (9.3); CG, PreM:
31.3 (9.2); PostM:
33.6 (8.7) wk
Sx: 100; CT: 91; RT: 78; HT: 84 –
Schmitz 2010 RCT 154 55 (12) 28 (0) DCIS: 1; I: 56; II: 9; III: 34 IG: 39 (15); CG: 42 (16) m
o post diagnosis
Sx: 100; CT: 71; RT: 76; HT: 35 2 nodes removed; No LD
Schneider 2007 Pre-post 96 56 (10) BW (kg) A: 76 (19) NR NR Sx: 99; CT: 50; RT: 43 –
Scott 2013 RCT 90 56 (9) 30 (0) I/II/III 3 to 18mo Mast: 41; Lump: 59; CT: 56;
RT: 83; HT: 78
BMI >25; Inactive
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Table 1 (Continued )
Reference Study
design
Patient characteristics
n Age (yr) BMI (kg/m2) Stage (%) Time since treatment Treatment type (%) Eligibility
criteria
mean
(SD/range)
mean (SD) mean (SD)
Smoot 2010 Obs 144 56 (12) 26.1 (5) NR No LD: 5 (4)
LD: 7 (6) yr post diagnosis
Lump: 57; Mast: 43; CT:
70; RT: 74
–
Sprod 2005 RCT 12 53 (3) BW (lb) 179 (17) NR IG: 20 (5); CG: 26 (5) mo Sx: 100; Mast: 92; CT:
83; RT: 58
–
Sprod 2010 Pre-post 114 59 (0) BW (lb) 169 (11) NR IG3: 13 (1); IG6: 29 (1);
CG: 35 (5) mo
CT: 60; RT: 40 –
Taylor 2010 RCT 260 55 (9) 31 (5) IA: 42; IB: 3; IIA: 20;
IIB: 2; IIIA: 23; IIIB:
0.1; DCIS: 6
5 (3) yr post diagnosis Sx: 10; Sx+CT: 13; Sx+ RT:
26; Sx+ CT+RT: 49
BMI > 25.0
Tolentino 2010 Obs 22 49 (9) 27 (4) IIA: 18; IIB: 41; IIIA: 41 <14mo post diagnosis Sx+CT+RT: 100 –
Tosti 2011 Obs 7 51 (3) 29 (1) I: 14; II: 43; III: 43 < 6mo Sx: 100; CT: 71 RT: 86; HT: 86 –
Turner 2004 Pre-post 10 47 (8) NR NR 17 a (4 to 60) mo Sx+CT+RT: 100 –
Twiss 2009 RCT 223 59 (8) 27 (4) 0/I/II 6 (6) yr Sx: 98; RT: 45; CT: 68; HT: 50 BMD < –1.0; Inactive PostM
Wampler 2007 Obs 20 50 (9) BW (kg) 68 (9) NR < 30d CT: 100 Taxane-based CT
Winters-Stone 2008 Obs 47 68 (7) NR 0: 3; I: 37; II: 22; III: 7 8 (7) yr post diagnosis RT: 58; CT: 37; HT: 48 >60yr old
Winters-Stone 2011 Obs 59 59 (10) 28 (7) 0: 5; I: 29; II: 39; III: 19 < 2yr CT: 29; HT: 32; CT+HT: 39 < 70yr, PostM
Winters-Stone 2012 RCT 106 62 (10) IG: 30 (6)
CG: 30 (6)
0: 6; I: 40; II: 42; III: 6 IG: 57 (40); CG: 65 (35)
mo post diagnosis
CT: 60; RT: 88; HT: 57 > 50yr at diagnosis;
Inactive, PostM
Yuen 2007 RCT 22 54 (12) NR NR 9d to 35mo Sx: 100; Mast: 41; Lump: 55;
CT: 82; RT: 77
Inactive; Moderate fatigue
AI =Aromotase inhibitors, AET=aerobic exercise training, BW=body weight, BMI=Body Mass Index, CG=control group, CT= chemotherapy, HER-2/neu=human epidermal growth factor receptor 2, HT=hormonal therapy, IG= intervention
group, Lump= lumpectomy, LD= lymphoedema, Mast =mastectomy, NR=not reported, Obs=observational study, Pre-post =pre-post non-randomised intervention, PreM=premenopausal, PostM=postmenopausal, RCT= randomised controlled
trial, RET= resistance exercise group, RT= radiation therapy, SE= standard error, Sx= surgery, Tam=Tamoxifen.
a Median reported instead of mean.
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Figure 2. Forest plot of weighted mean (95% CI) VO2peak corrected for body weight
from a maximal exercise test. References to included studies are available in
Appendix 2 in the eAddenda.
AET = aerobic exercise training, CG = control group, IG = intervention group, RET =
resistance exercise training.
Table 2
Normative values for common tests of physical function.
Aerobic capacity
Cardiopulmonary exercise test, VO2max (mL/kg/min); females only
11
very poor
poor
fair
good
excellent
superior
Age 40 to 49
22.2 to 28.2
29.4 to 32.3
32.8 to 35.2
35.9 to 38.6
39.6 to 43.1
45.3 to 51.1
Age 50 to 59
20.1 to 25.8
26.8 to 29.4
29.9 to 32.3
32.6 to 35.2
36.7 to 38.8
41.0 to 46.1
Age 60 to 69
19.5 to 23.9
24.6 to 26.6
27.3 to 29.4
29.7 to 32.3
32.7 to 35.9
37.8 to 42.4
6-minwalkdistance (m) in communitydwellingadults, reportedasmean(SD) 28
10th percentile
25th percentile
50th percentile
75th percentile
90th percentile
Age 60 to 64
452.6
498.3
553.2
603.5
649.2
Age 65 to 69
402.3
457.2
521.2
580.6
635.5
Age 70 to 74
384.0
438.9
502.9
562.4
617.2
Upper extremity strength
Grip strength (kg) 29
5th percentile
median
Age 40 to 49
21.8
28.6
Age 50 to 59
20.4
27.7
Age 60 to 69
18.1
25.4
Bench press one repetition max (weight pushed/body weight) 11
very poor
poor
fair
good
excellent
superior
Age 40 to 49
<0.35 to 0.42
0.43 to 0.48
0.50 to 0.53
0.54 to 0.60
0.62 to 0.71
> 0.77
Age 50 to 59
< 0.31 to 0.38
0.39 to 0.43
0.44 to 0.47
0.48 to 053
0.55 to 0.61
> 0.68
Age 60+
< 0.26 to 0.36
0.38 to 0.41
0.43 to 0.46
0.47 to 0.53
0.54 to 0.64
> 0.72
Elbow ﬂexion (kg) obtained using hand-held dynamometry, reported as
mean (SD) 42
dominant
non-dominant
Age 50 to 59
17.0 (2.9)
16.3 (2.7)
Age 60 to 69
16.0 (3.0)
15.4 (2.7)
Age 70 to 79
14.1 (2.7)
14.4 (2.4)
Lower extremity strength
Leg press one repetition max (weight pushed/body weight) 11
well below average
below average
average
above average
well above average
Age 40 to 49
0.94 to 1.02
1.08 to 1.13
1.18 to 1.23
1.29 to 1.37
> 1.48
Age 50 to 59
0.78 to 0.88
0.95 to 0.99
1.05 to 1.10
1.17 to 1.25
> 1.37
Age 60+
0.72 to 0.85
0.88 to 0.93
0.99 to 1.04
1.13 to 1.18
> 1.32
Chair stands (number in 30s), reported as mean (SD) 28
Age 60 to 64
13.3 (3.6)
Age 65 to 69
13.7 (3.5)
Age 70 to 74
12.8 (3.1)
Knee ﬂexion (kg) obtained using hand-held dynamometry, reported as
mean (SD) 42
dominant
non-dominant
Age 50 to 59
17.2 (4.1)
17.3 (4.7)
Age 60 to 69
16.0 (2.8)
15.6 (3.0)
Age 70 to 79
14.0 (3.5)
14.4 (3.9)
Mobility
Timed Up and Go (s), reported as mean (SD)
3-m course 43 Age 40 to 49
6.24 (0.67)
Age 50 to 59
6.44 (0.17)
Age 60 to 69
7.24 (0.17)
8-foot course 28 Age 60 to 64
5.4 (1.2)
Age 65 to 69
5.6 (1.0)
Age 70 to 74
6.0 (1.3)
Neil-Sztramko et al: Physical function after breast cancer diagnosis196Upper extremity muscular ﬁtness
Grip strength was the most commonly used upper extremity
function test; it was used in 26 studies (see Table 3 in the
eAddenda). Themean of the grip strength data that could be pooled
was 24.6 kg (95% CI 23.7 to 25.5) in women on treatment and
22.8 kg (95% CI 20.6 to 25.1) in women off treatment (Figure 7).
These values fall below the median reported values of 27.7 kg for
healthy adults aged 50 to 59 (Table 2).29 No heterogeneity was
identiﬁed (I2 values < 20%).
1RMusing a bench or chest press protocolwas estimated in four
studies andmeasured directly in four studies. The pooled mean for
bilateral bench press 1RM was 20.9 kg (95% CI 17.0 to 24.7) in
women on treatment and 23.9 kg (95% CI 21.0 to 26.8) in women
off treatment (Figure 8). Moderate heterogeneity was identiﬁed
(I2 = 36%) for women off treatment. Normative values for 1RM arereported in weight pushed per kg of body weight, but for a woman
weighing 70 kg, these pooled values fall into the ‘very poor’
category across all age groups (Table 2).11 Other methods of
assessing upper extremity strength include a bench press 6RM,
bench press endurance with various protocols, and elbow ﬂexion.
Lower extremity muscular ﬁtness
The most commonly reported test of lower extremity strength
was the 1RM for leg press, estimated in three studies andmeasured
in ﬁve studies (see Table 4 in the eAddenda). The pooled mean for
1RMwas 67.6 kg (95% CI 61.2 to 73.8) for women on treatment and
95.8 kg (95% CI 88.3 to 103.4) for women off treatment (Figure 9).
Heterogeneity was found to be substantial for women off
treatment only (I2 = 69%). Reported normative values are reported
in weight pushed per kg of bodyweight, but for a womanweighing
70 kg, values for women on treatment fall into the ‘below average’
category for women aged 50 to 59, while values for women off
treatment fall into the ‘above average’ category for women aged
50 to 59 (Table 2).11 A leg-press protocol was also used to measure
maximum isometric contraction and muscle endurance. Other
protocols requiring resistance-training equipment include knee
ﬂexion and knee extension machines. Chair stands were also used
as a functional measure of lower extremity function (n = 7),
although pooled analysiswas not possible due to the heterogeneity
of protocols used.
Mobility
The TUG test was used to evaluate functional mobility in two
included studies (see Table 5 in the eAddenda). However, the
results from the two are not directly comparable as they used two
different protocols: one used an 8-foot course and the other a 3-
metre course. In both studies, reported times were slower than
population normative values for similar age groups (Table 2).
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Figure 4. Forest plot of weighted mean (95% CI) VO2max estimated from a
submaximal exercise test. References to included studies are available in Appendix
2 in the eAddenda.
AET = aerobic exercise training, CG = control group, CT = chemotherapy,
ExCG = exercise control group, IG = intervention group, RET = resistance exercise
training, RT = radiotherapy, Sx = surgery. a Cycle ergometer.
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Figure 3. Forest plot of weighted mean (95% CI) VO2peak from a maximal exercise
test. References to included studies are available in Appendix 2 in the eAddenda.
AC = four cycles of adjuvant chemotherapy with doxorubicin/cyclophosphamide,
AET = aerobic exercise training, CG = control group, FC = ﬁve cycles of 5-ﬂuorouracil/
epirubicin/cyclophosphamide, IG = intervention group, RET = resistance exercise
training.
Research 197Discussion
Monitoring physical function during and after cancer treatment
may help physiotherapists and other health professionals to
identify declines in physical function, and prescribe interventions
to mitigate these declines and improve functional outcomes. We
aimed to summarise the published values in the literature to date
in order to provide clinicians with expected values in this
population for the tests of physical function most commonly
reported in the literature and to inform clinicians and researchers
of testing options. A longer-term goal of the research is greater
standardisation of testing in both clinical and research settings.We
also aimed to compare the values that are currently being reported
in women who have been diagnosed with breast cancer to
normative values that have been published in healthy populations,
with the goal of contextualising the physical function deﬁcits
experienced by women with breast cancer.
Reported values of aerobic capacity, upper extremity strength
andmobility were generally lower than reported normative values
in similar age groups. Thiswas not surprising given the various side
effects of cancer treatment and fatigue leading to decline in overall
physical activity. Jones and colleagues compared VO2peak
between women with breast cancer at various stages of the
disease and expected values for healthy sedentary women.10
Similar to the ﬁndings of the present review, VO2peak was much
lower in women diagnosed with breast cancer than would be
expected. Women in the Jones study who were 50 years old and
diagnosed with breast cancer were on average 30% less aerobically
ﬁt, which is similar to the present review’s ﬁnding that pooledmean reported VO2peak values were 22 to 30% lower than
published norms for those aged 50 to 59.
An important consideration when comparing results across
studies is the age range of the participants. While mean ages were
extracted from the papers included, individual level data would be
needed in order to compare values of physical function amongst
different age groups. For example, aerobic capacity has been
shown to decline by approximately 9% per decade after the age of
50, so comparisons of mean VO2peak values across a wide range of
ages may not be appropriate.30
In the present meta-analysis, pooled values of all measures of
aerobic capacity and grip strength were lower for women who
were off treatment than women who were on treatment. The
opposite was observed for bench press and leg press 1RM values.
Findings from 1RM should be interpreted with caution, due to its
substantial heterogeneity among women off treatment. The 1RM
data were a combination of estimated and objectively measured
values. It is possible that the predictive equations used to estimate
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Figure 6. Forest plot of weighted mean (95% CI) 12-minute walk distance.
References to included studies are available in Appendix 2 in the eAddenda.
AET = aerobic exercise training, CG = control group, IG = intervention group,
RET = resistance exercise training.
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Figure 5. Forest plot of weightedmean (95% CI) 6-minute walk distance. References
to included studies are available in Appendix 2 in the eAddenda.
AET = aerobic exercise training, CG = control group, IG = intervention group,
RET = resistance exercise training.
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Figure 7. Forest plot of weighted mean (95% CI) grip strength. References to
included studies are available in Appendix 2 in the eAddenda.
CG = control group, IG = intervention group, L = left, LO = lymphoedema, NoLO = no
lymphoedema, R = right.
Neil-Sztramko et al: Physical function after breast cancer diagnosis1981RM overestimated the true value. The timing of measurement
also varied between studies, which should be kept in mind when
comparing groups on and off treatment. Women classiﬁed as on
treatment may have completed surgery, or been at any pointduring chemotherapy or radiation; however, the majority were
assessed at the beginning of chemotherapy treatment. Women
classiﬁed as off treatment ranged from a fewmonths tomany years
after treatment. Future observational studies repeating measures
of physical function before, during, and after treatment are needed
to more accurately determine the expected pattern of change in
physical function throughout the cancer trajectory.
Another source of variation between studies was the speciﬁc
testing protocol used. Submaximal and maximal exercise tests
may be performed on either a cycle ergometer or a treadmill and
may use a ramp or incremental protocol with a number of
possibilities in length of test stage and workload increment per
stage. Values for VO2peak have been shown to be higher using a
treadmill than cycle ergometer protocol in women diagnosed with
breast cancer.31 Values for upper and lower extremity strength,
such as grip strength, maximal contraction for leg press, or knee
ﬂexion/extension, may be reported as average of three trials or
maximumvalue obtained. Therewas also variation in the protocols
used for assessing muscular endurance and the chair stand test,
which prevented pooling of the results together. This highlights the
importance of reporting full details of the testing protocol in order
to determine whether comparisons can be made between studies.
Overall, 56 (66%) studies included some measure of aerobic
capacity, indicating recognition of the importance of this compo-
nent of health-related physical ﬁtness. The most common method
of measurement used was the gold-standard, maximal, cardiopul-
monary exercise test, followed by a submaximal exercise test
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Figure 8. Forest plot of weightedmean (95% CI) one-repetitionmaximum (1RM) for
bench press. References to included studies are available in Appendix 2 in the
eAddenda.
AET = aerobic exercise training, CG = control group, IG = intervention group,
RET = resistance exercise training.
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Figure 9. Forest plot of weightedmean (95% CI) one-repetitionmaximum (1RM) for
leg press. References to included studies are available in Appendix 2 in the
eAddenda.
AC = four cycles of adjuvant chemotherapy with doxorubicin/cyclophosphamide,
AET = aerobic exercise training, CG = control group, FC = ﬁve cycles of 5-ﬂuorouracil/
epirubicin/cyclophosphamide, IG = intervention group, RET = resistance exercise
training.
Research 199terminated at a speciﬁed percentage of age-predicted heart rate
reserve or maximal heart rate. Although formal, large-scale
assessment of the safety of the cardiopulmonary exercise testing
procedure in individuals with cancer has not been performed, it
does appear to be relatively safe with appropriate screening and
monitoring during the test.32 Submaximal exercise testing is
considered to be a safer option, and may not require medical
supervision, but is not as accurate for quantifying VO2peak.
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Finally, walking tests (6MWT and 12MWT) were commonly
reported. Research is needed to determine if the 12MWT is a more
appropriate test for capturing physical function in women with
breast cancer than the 6MWT. It may be that women diagnosed
with breast cancer have greater physical capacity than individuals
in cardiac and pulmonary rehabilitation where the 6MWT is
commonly used, and thereforemay experience a ceiling effect with
the 6MWT.12
Grip strength was the most commonly used measure of
strength in this review and has been recommended as an
assessment of muscle function for oncology rehabilitation.33 Grip
strength dynamometry is an attractive measure of strength in all
populations due to its ease of use, reliability, generalisability to
overall strength, and availability of published age and gender
norms.22 Additionally, grip strength is reported to be a signiﬁcant
predictor of health-related quality of life in breast cancer
survivors.34 While 1RM testing may be more sensitive and speciﬁc
for strength training interventions, the small number of studies
performing 1RM testing for upper body testing could be attributed
to fear of musculoskeletal injury in a population likely to be naı¨ve
to strength training, and concern regarding risk of precipitating
lymphoedema. However, guidelines from the American College of
Sports Medicine published in 2010 advocate that 1RM testing is
safe in womenwith breast cancer, even those with or at higher risk
for lymphoedema.35
Only two studies included measurements of mobility. This may
be because the TUG test and other mobility tests have been
developed for and validated in older adults,25 and thus may not be
sufﬁciently sensitive to capture impairment experienced following
breast cancer treatment. An alternative explanation is that
mobility impairments following breast cancer and its treatment
have not been widely recognised in the literature, and as a
result few studies have measured this. Thus the utility of mobility
testing in this population requires further investigation.One limitation of this review is the likely presence of selection
bias in the individuals included in the research studies, limiting the
generalisability of these results to all women diagnosed with
breast cancer. Due to the nature of the outcome measures of
interest in this review, many of the studies included were physical
activity interventions. While some studies did restrict eligibility to
women who were sedentary or not currently exercising routinely,
due to the nature of the intervention, these studies likely recruited
a select group who were the most healthy or health-conscious.
Other studies speciﬁcally limited their study populations to
women who experienced functional limitations36–40 or women
with lymphoedema.8,41 In these cases, values below those reported
for the average woman diagnosed with breast cancer can be
expected. Other studies excluded women with functional pro-
blems that may be worsened by exercise, such as shoulder pain.
Therefore, we decided to include all relevant papers with the
caveat that results from individual studies reported may be more
relevant to different subgroups of women diagnosed with breast
cancer, and the pooled meta-analysis may not be applicable to all
women. As more research becomes available, future work should
aim to analyse physical function in these groups of women
separately.
One strength of this review is the inclusion of objective gold-
standard tests of physical function, such as measured VO2peak and
1RM testing for muscular strength. While these tests may provide
the best assessment of physical function, they require the use of
specialised, often expensive equipment and individuals who have
been trained to conduct the testing. Therefore, submaximal and
ﬁeld tests to estimate maximal values are invaluable in clinical
practice, and may also be quite useful in some research settings. A
second strength is the meta-analysis used to combine data from
multiple studies, which provides a general estimate of expected
values in this population.
This review summarises the values that have been reported in
the literature to date for various components of physical function,
Neil-Sztramko et al: Physical function after breast cancer diagnosis200namely aerobic capacity, upper and lower extremity strength and
mobility in women diagnosed with breast cancer. Values for
aerobic capacity and upper extremity strength are generally lower
than published normative values in similar age groups. Lower
extremity strength does not appear to follow this pattern, with
values higher than population norms. This review also highlights
the variety of tests used in the literature to assess physical function
and the variations in testing protocols that may potentially
contribute to the heterogeneity in values reported. Objective
assessments of various aspects of physical function are important
for documenting deﬁcits in physical function and reporting change
in response to speciﬁc interventions and monitoring individual
progress in physiotherapy practice and research settings. As more
research becomes available, expected values for sub-populations
of different ages, stages of treatment and with various co-
morbidities will be useful for both researchers and clinicians
working with women after a breast cancer diagnosis.What is already known on this topic: Breast cancer and its
treatment can cause impairment in physical function in wom-
en.
What this study adds: Compared to normative data, women
during and after treatment for breast cancer had reduced
aerobic fitness. Upper and lower extremity strength was also
reduced for women who were currently receiving cancer
treatment. Lower extremity strength was above population
norms for women who had completed treatment.eAddenda: Tables 3, 4, 5 and 6, and Appendix 1 and 2 can be
found online at doi:10.1016/j.jphys.2014.09.005
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